If left untreated, a bout of uncomplicated malaria can quickly evolve into severe malaria, which may have life-threatening consequences. Timely access to the appropriate treatment for uncomplicated malaria is key to avoiding this scenario.
Eurartesim is a fixed-dose combination of dihydroartemisinin-piperaquine (DHA-PQP), developed by Alfasigma S.p.A. in partnership with MMV, for the treatment of acute uncomplicated P. falciparum malaria. Studies have also shown that DHA-PPQ’s long half-life affords patients a useful period of protection from new malaria infections.1 2
An essential medicine recommended by WHO
Eurartesim obtained marketing authorization from the European Medicines Agency (EMA) in 2011 and in 2015, the medicine was prequalified by WHO. In June 2017, Eurartesim was added to WHO’s Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) after a successful application by Alfasigma.
In 2015, Alfasigma entered into an exclusive licensing agreement with Pierre Fabre to expand its ability to support country registration requirements and national adoption of Eurartesim in 32 African countries. To date, over 4.5 million treatments of Eurartesim have been distributed since approval by the EMA.
Alfasigma will submit a regulatory dossier to the EMA for a new dispersible formulation of Eurartesim designed specifically to address the treatment needs of children.
→Take a look at the interactive map to see where Eurartesim is registered.